PURPOSE: Lifitegrast ophthalmic solution 5% (Xiidra) is indicated for the treatment of signs and symptoms of dry eye disease (DED). The purpose of this study was to examine real-world utilization and outcomes of lifitegrast ophthalmic solution in patients with DED via quantitative (provider survey) and qualitative (case studies) analyses.

METHODS: Eyecare providers (12 ECPs: 6 ophthalmologists and 6 optometrists) treating patients with DED were invited to complete a provider survey. The survey included items regarding timing and degree of symptom resolution with lifitegrast treatment, satisfaction with onset of action, and effectiveness of lifitegrast in treating DED (rated on a scale from 0 [very dissatisfied]) to 10 [very satisfied]). The survey also evaluated use of lifitegrast in patients with DED combined with other ocular conditions (eg, contact lens wear; refractive, cataract, and vitreoretinal surgery; keratoplasty). ECPs also provided case study data for up to five patients with DED who initiated lifitegrast treatment.

RESULTS: 12 ECPs treated an average of 1288 patients with DED annually, with 21% of these patients, on average, receiving lifitegrast. 7 ECPs provided 33 case reports. Nearly all ECPs (92%) reported treating contact lens–induced DED with lifitegrast. Other predominant uses of lifitegrast included DED prior to or after refractive or cataract surgery (83% each). Two-thirds (67%) of ECPs reported near/complete symptom resolution in patients after 1-3 months of lifitegrast treatment. Satisfaction ratings (mean [range]) for onset and effectiveness were 6.8 (3-9) and 6.6 (3-9), respectively. Improvement was sustained during treatment up to 12 months, supported by case data (mean [range], 15 [1-69] months).

CONCLUSIONS: Quantitative survey and qualitative case data highlight the rapid and durable response associated with lifitegrast for the treatment of patients with DED. Lifitegrast is used frequently in the management of DED in contact lens wearers and in patients undergoing various ocular surgeries.